Request Demo
Last update 05 Nov 2025
Rituximab biosimilar (Chia-tai Tianqing)
Last update 05 Nov 2025
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms Rituximab Biosimilar (Chia Tai Tianqing Pharmaceutical Group Co., Ltd.), 利妥昔单抗生物类似药（Chia Tai Tianqing Pharmaceutical Group Co., Ltd.）, TQB 2303 + [2] |
Target |
Action inhibitors |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 27145L
The sequence is quoted from: *****
Sequence Code 83181H
The sequence is quoted from: *****
Related
10
Clinical Trials associated with Rituximab biosimilar (Chia-tai Tianqing)ChiCTR2500106326
A Prospective, Single-Arm, Phase II Clinical Study of RP Regimen in Previously Untreated Indolent B-Cell Lymphoma
CTR20250154
TQB2825注射液联合免疫化疗在弥漫大B细胞淋巴瘤受试者中的Ib/II期临床试验
[Translation] Phase Ib/II clinical trial of TQB2825 injection combined with immunochemotherapy in subjects with diffuse large B-cell lymphoma
CTR20250307
TQB2825注射液联合化疗在复发/难治性弥漫大B细胞淋巴瘤受试者中的II期临床试验
[Translation] Phase II clinical trial of TQB2825 injection combined with chemotherapy in subjects with relapsed/refractory diffuse large B-cell lymphoma
100 Clinical Results associated with Rituximab biosimilar (Chia-tai Tianqing)
Login to view more data
100 Translational Medicine associated with Rituximab biosimilar (Chia-tai Tianqing)
Login to view more data
100 Patents (Medical) associated with Rituximab biosimilar (Chia-tai Tianqing)
Login to view more data
100 Deals associated with Rituximab biosimilar (Chia-tai Tianqing)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| CD20 positive Diffuse Large B-Cell Lymphoma | China | 26 May 2023 | |
| Chronic Lymphocytic Leukemia | China | 26 May 2023 | |
| Follicular Lymphoma | China | 26 May 2023 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| CD20 positive Non-Hodgkin Lymphoma | Phase 2 | China | 01 May 2017 |
Login to view more data
Clinical Result
Clinical Result
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free